Stock, market, and fund insights for July 2021 available on our platform.
Moderna, the biotech company that made waves with its groundbreaking COVID-19 vaccine, is now setting its sights on a broader horizon. The company is actively expanding its portfolio, focusing on vaccines for cytomegalovirus (CMV), cancer, AIDS, and other diseases.
In the realm of infectious diseases, Moderna is making significant strides. The company's mRNA-1647 vaccine candidate for CMV is currently in a pivotal Phase 3 trial. The trial, fully enrolled and with sufficient cases for primary endpoint evaluation, is aimed at preventing primary infection in women of childbearing age. Moderna expects to conduct a final Phase 3 analysis in 2025, with an updated analysis plan that includes additional secondary endpoints.
For norovirus, Moderna is conducting a Phase 3 trial (mRNA-1403), with results pending and dependent on case accrual. The company has also secured FDA approval for its respiratory syncytial virus (RSV) vaccine, mResvia, for use in at-risk adults.
In the fight against cancer and AIDS, while late-stage trial details are not yet specified, Moderna's mRNA platform is being actively used to develop therapeutics and vaccines across immuno-oncology and rare and autoimmune diseases. This indicates ongoing research and development efforts in cancer vaccines and potential work towards AIDS vaccines, in line with their broader portfolio in mRNA medicines.
Moderna is also advancing next-generation vaccines that combine multiple targets, such as the flu/COVID combination vaccine, mRNA-1083, which showed positive Phase 3 immunogenicity data in adults aged 50 and older.
Financially, despite a recent decline in COVID-19 vaccine sales, Moderna continues to enjoy a strong regulatory approval streak and is focusing its R&D efforts on broadening its product pipeline beyond COVID-19. The company acknowledges that mRNA technology remains its core strength but faces commercialization challenges, pushing them to diversify within infectious diseases and possibly beyond mRNA to sustain growth.
The increase in Moderna's stock price, currently trading at around $336 on July 26, 2021, reflects the company's initial results and future plans, including its work beyond COVID-19 vaccines. The company has already secured a contract for 20 million doses of COVID-19 vaccine in 2022 from Taiwan, with an additional 15 million doses in the following year. Moderna aims to exceed one billion doses for the full year, having shipped 102 million doses in the first quarter alone.
In conclusion, Moderna's current status is the continued rollout and approval of improved COVID-19 vaccines alongside advancing Phase 3 studies in CMV and norovirus vaccines, approved RSV vaccines, and ongoing development in cancer and AIDS vaccine candidates using mRNA technology. Key results and potential approvals are expected within 2025. The company's stock price growth may continue to be influenced by its success in these areas.
[1] Moderna. (2021). Moderna Announces Full Enrollment and Accrual of Sufficient Cases for Primary Endpoint Evaluation in Phase 3 CMV Vaccine Trial. [online] Available at: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-full-enrollment-and-accrual-sufficient-cases
[2] Moderna. (2021). Moderna Announces Update to mRNA-1647 Phase 3 CMV Vaccine Trial Analysis Plan to Include Additional Secondary Endpoints. [online] Available at: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-update-mrna-1647-phase-3-cmv-vaccine-trial
[3] Fierce Biotech. (2021). Moderna's COVID-19 vaccine sales slow, but company focuses on R&D to broaden product pipeline. [online] Available at: https://www.fiercebiotech.com/biotech/modernas-covid-19-vaccine-sales-slow-but-company-focuses-on-rd-to-broaden-product-pipe
[4] Moderna. (2021). Moderna Announces Positive Phase 3 Immunogenicity Data for mRNA-1083, its Influenza Vaccine Candidate. [online] Available at: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-phase-3-immunogenicity-data-mrna-1083
[5] Moderna. (2021). Moderna Announces Update to mRNA-1647 Phase 3 CMV Vaccine Trial Analysis Plan to Include Additional Secondary Endpoints. [online] Available at: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-update-mrna-1647-phase-3-cmv-vaccine-trial
Science and finance have intertwined in Moderna's journey to expand its portfolio beyond COVID-19 vaccines. With a focus on vaccines for cytomegalovirus (CMV) and other diseases, the company is currently conducting a Phase 3 trial using its mRNA technology, aiming to prevent primary infection in women of childbearing age (Moderna, 2021). In the health-and-wellness sector, investment in research and development continues, with ongoing work in immuno-oncology, rare and autoimmune diseases, and potential AIDS vaccine candidates (Fierce Biotech, 2021).
